Golden State Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Golden State Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.35K	Sell	15 -5	-25%	-$3.4K	﹤0.01%	1134
2026 Q1	$15.5K	Hold	20	–	–	﹤0.01%	982
2025 Q4	$15.4K	Hold	20	–	–	﹤0.01%	990
2025 Q3	$11.2K	Hold	20	–	–	﹤0.01%	1073
2025 Q2	$10.5K	Sell	20 -6	-23%	-$3.35K	﹤0.01%	1067
2025 Q1	$16.5K	Hold	26	–	–	﹤0.01%	849
2024 Q4	$18.5K	Buy	+26	New	+$21.8K	﹤0.01%	785
2022 Q1	$274K	Sell	393 -6	-2%	-$3.8K	0.05%	251
2021 Q4	$252K	Sell	399 -30	-7%	-$18.4K	0.04%	318
2021 Q3	$260K	Sell	429 -9	-2%	-$5.59K	0.06%	251
2021 Q2	$245K	Buy	438 +1	+0.2%	+$507	0.05%	254
2021 Q1	$206K	Buy	+437	New	+$213K	0.07%	194
2020 Q2	–	Sell	-300	Closed	-$146K	–	767
2020 Q1	$146K	Buy	+300	New	+$124K	0.06%	194

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Golden State Wealth Management's REGN Position: Q2 2026 in Review

Golden State Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, selling an estimated $3.4K and leaving 15 shares worth $9.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Golden State Wealth Management first reported a position in REGN in Q1 2020 and has held it in 13 quarters since. The position peaked at $274K in Q1 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Golden State Wealth Management held 15 shares of Regeneron Pharmaceuticals worth $9.35K as of Q2 2026.
Golden State Wealth Management sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
Regeneron Pharmaceuticals made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1134 holding.
Golden State Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
Golden State Wealth Management's Regeneron Pharmaceuticals position peaked at $274K in Q1 2022.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.